An Evaluation of the Efficacy of High-dose Hepatitis B Vaccine in Patients Using Biological Agents
Journal Title: Viral Hepatitis Journal - Year 2020, Vol 26, Issue 2
Abstract
Objectives: Hepatitis B virus (HBV) vaccination is efficient in the normal population, whereas lower humoral response rates in immunosuppressed patients. Biological agents used in the treatment of several diseases in recent years are a significant cause of immunosuppression in patients. In this study we aimed to evaluate the efficacy of double-dose HBV vaccination at months 0, 1, 2, and 6 in patients using biological agents. Materials and Methods: The patients who were using biological agents and seronegative for HBV received double-dose HBV vaccine (40 μg) on months 0, 1, 2 and 6, and response rates were assessed. Patients with anti-HBs titers >10 mIU/mL one month after completion of the vaccine plan were regarded as vaccineresponsive. Results: Eighty-four patients were evaluated. Forty patients (47.4%) were men and 44 (52.4%) were women. The mean age of the patients was 43.1±12.5 years. The most common underlying inflammatory rheumatic disease was ankylosing spondylitis at 51.2% (n=43). The most commonly used biological agent was adalimumab at 36.9% (n=31). Vaccine response was achieved in 85.7% (n=72) of the patients, while no response was achieved in 12 patients (14.3%). Sex, comorbidities, type of underlying inflammatory disease and biological agents had no effect on vaccine response. Conclusion: Administration of 40 μg HBV vaccine at months 0, 1, 2, and 6 to HBV seronegative patients using biological agents was found to be effective. This efficacy was found to be independent of the type of biological agent, the time of onset of the biological agent and the length of use of the biological agent.
Authors and Affiliations
Murat Aydın, Firdevs Aksoy, Zehra Yıldırım, İftihar Köksal
Keywords
Related Articles
- EP ID EP688806
- DOI 10.4274/vhd.galenos.2020.2019.0039
- Views 145
- Downloads 0
The Impact of COVID-19 Pandemic on Treatment, Follow-up and Behavioral Characteristics of Chronic Viral Hepatitis Patients
Objectives: It has been not yet fully understood whether chronic liver diseases may be considered as risk factors for critical course of Coronavirus disease-2019 (COVID-19). Considering the importance of managing with CO...
Examination of Mutations in the HBsAg and Polymerase Genes Induced by Pegylated Interferon Alpha and Oral Antivirals Used in the Treatment of Chronic Hepatitis B
Objectives: The Hepatitis B Virus is a virus having high mutation frequency due to having a high replication capacity and not having error correction capability in reverse transcription.It is aimed to examine the mutatio...
The Importance of Antiviral Prophylaxis against Hepatitis B Virus in Patients under Immunosuppressive Therapy
Objectives: Immunosuppressive (IS) therapies present a risk of reactivation in patients with previous or known hepatitis B virus (HBV) infection and may cause mortality and morbidity. Before starting these therapies, pat...
Genotyping Distribution of Hepatitis C Virus in Şanlıurfa Province and Effect of Syrian Patients
Objectives: Hepatitis C virus (HCV) is one of the major causes of global mortality and morbidity. The purpose of our study was to characterize the distribution of HCV genotypes in Şanlıurfa, to see the effect of patients...
Genotype Distributions and Hepatitis B Coinfection in Hepatitis C Patients at a University Hospital
Objectives: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Comorbidity with the hepatitis B virus (HBV) leads to progressive fibrosis and severe liver disease. Our study aimed to determine H...